GE HealthCare Technologies' (NASDAQ: GEHC) MIM Software recently announced the receipt of FDA clearance for performing Centiloid scaling for positron emission tomography (PET)-based amyloid imaging analysis and quantification.
With MIMneuro, a vendor-neutral solution, this new Centiloid scale tool is likely to be able to assist physicians in more accurately determining the density of amyloid plaque in a patient's brain. Amyloid PET radiotracers help visualize amyloid plaque density in patients being evaluated for Alzheimer's disease.
Likely Trend of GEHC Stock Following the News
Following the announcement, shares of the company moved nearly 1.7% north to $88.53 at yesterday's close.
GE HealthCare is one of the leading providers of medical technology, pharmaceutical diagnostics, and digital solutions with a focus on precision care. In March, GE Healthcare acquired MIM Software, which added AI-based solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics and research organizations worldwide. Owing to the strong potential for the diagnostic imaging market, we expect the market sentiment to remain positive around this news.
Meanwhile, GEHC currently has a market capitalization of $39.63 billion. It has an earnings yield of 4.91% is much higher than the industry's yield of negative (7.12)%. In the last reported quarter, GEHC delivered an earnings surprise of 2.04%.
More on the GEHC's Centiloid Scaling Tool
A significant number of people in the United States develop dementia, with Alzheimer's disease accounting for 60-80% of dementia cases. The condition affects memory, thinking and behavior, and symptoms typically start with ...
